Innate Pharma S.A. - Depositary Receipt Price Target Increased by 27.91% to $8.22

The average one-year price target for Innate Pharma S.A. - Depositary Receipt (NASDAQGS:IPHA) (MUN:IDDA) has been revise...

By Dhallo News · October 2, 2026 at 5:14 PM IST

The average one-year price target for Innate Pharma S.A. - Depositary Receipt (NASDAQGS:IPHA) (MUN:IDDA) has been revised to $8.22 / share. This is an increase of 27.91% from the prior estimate of $6.43 dated September 13, 2026. These figures represent aggregate analyst targets c

SOURCE: Nasdaq

ORIGINAL REPORT: Click here

DHALLO EDITORIAL STATUS: Aggregated & reviewed

Have feedback on this article?Report error or suggestion

Innate Pharma S.A. - Depositary Receipt Price Target Increased by 27.91% to $8.22

Read More from Markets

RBI MPC may hike repo rate next week: Experts share the equity-debt strategy investors should consider

Immix Biopharma Consensus Price Target Increased by 10.16% to $25.04

Karat Packaging Consensus Price Target Raised 12.05% to $47.43

5 minutes. The news that matters.